Oncotarget, Vol. 7, No. 19
www.impactjournals.com/oncotarget/
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma Junjie Hang1,2,*, Hai Hu1,2,*, Junjie Huang3,*, Ting Han1,2, Meng Zhuo1,2, Yangyang Zhou4, Lei Wang5, Yi Wang1,2, Feng Jiao1,2, Liwei Wang1,2 1
epartment of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University D School of Medicine, Shanghai 201620, China
2
Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China
3
Department of Hematology, First Affiliated Hospital of Shenzhen University, Shenzhen 513000, China
4
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui 233004, China
5
Department of Radiation Oncology, Lianyungang First People’s Hospital, Jiangsu 222002, China
*
These authors contributed equally to this work
Correspondence to: Feng Jiao, email: [email protected] Liwei Wang, email: [email protected] Keywords: pancreatic ductal adenocarcinoma, specificity protein 1, cyclooxygenase-2, correlation, prognosis Received: January 17, 2016 Accepted: March 28, 2016 Published: April 5, 2016
ABSTRACT Previous studies showed that celecoxib, a cyclooxygenase-2 (COX2) inhibitor, can inhibit angiogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC) via the suppression of specificity protein 1 (Sp1). In this study, we investigated the prognostic value of Sp1 and COX2 in 88 PDAC patients. Our study showed there was a positive correlation between Sp1 and COX2 expression (P=0.001) by using the Spearman’s rank test. Pearson Chi-square test revealed that Sp1 and COX2 expression were positively associated with lymph node metastasis (P
www.impactjournals.com/oncotarget/
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma Junjie Hang1,2,*, Hai Hu1,2,*, Junjie Huang3,*, Ting Han1,2, Meng Zhuo1,2, Yangyang Zhou4, Lei Wang5, Yi Wang1,2, Feng Jiao1,2, Liwei Wang1,2 1
epartment of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University D School of Medicine, Shanghai 201620, China
2
Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China
3
Department of Hematology, First Affiliated Hospital of Shenzhen University, Shenzhen 513000, China
4
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui 233004, China
5
Department of Radiation Oncology, Lianyungang First People’s Hospital, Jiangsu 222002, China
*
These authors contributed equally to this work
Correspondence to: Feng Jiao, email: [email protected] Liwei Wang, email: [email protected] Keywords: pancreatic ductal adenocarcinoma, specificity protein 1, cyclooxygenase-2, correlation, prognosis Received: January 17, 2016 Accepted: March 28, 2016 Published: April 5, 2016
ABSTRACT Previous studies showed that celecoxib, a cyclooxygenase-2 (COX2) inhibitor, can inhibit angiogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC) via the suppression of specificity protein 1 (Sp1). In this study, we investigated the prognostic value of Sp1 and COX2 in 88 PDAC patients. Our study showed there was a positive correlation between Sp1 and COX2 expression (P=0.001) by using the Spearman’s rank test. Pearson Chi-square test revealed that Sp1 and COX2 expression were positively associated with lymph node metastasis (P
